Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Multicenter, Open-Label, Parallel-Group Study to Assess the Safety and Pharmacokinetics of Oral Epetraborole Tablets in Adult Subjects With Varying Degrees of Renal Function

Next Previous
Trial Profile

A Phase 1, Multicenter, Open-Label, Parallel-Group Study to Assess the Safety and Pharmacokinetics of Oral Epetraborole Tablets in Adult Subjects With Varying Degrees of Renal Function

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 01 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Epetraborole (Primary)
  • Indications Nontuberculous mycobacterium infections
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors AN2 Therapeutics

Most Recent Events

  • 11 Oct 2023 According to an AN2 Therapeutics media release, company will be presented data from this trial at the Infectious Disease Society of America (IDSA) IDWeek 2023 Conference from October 11-15, 2023 in Boston, Massachusetts.
  • 13 Jul 2022 Status changed from recruiting to completed.
  • 10 May 2022 According to an AN2 Therapeutics media release, topline results are expected in the second half of 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top